U.S. Physical Therapy, Inc, through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The company provides industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors As of March 14, 2019, it operated 592 outpatient physical therapy clinics in 42 states; and managed 28 physical therapy facilities for unaffiliated third parties, including hospitals and physician groups.
Read More…
Industry, Sector and Symbol
Industry Health services
Sub-IndustryHealth Care Facilities
SectorMedical
Phone713-297-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$453.91 million
Profitability
Miscellaneous
Employees4,600
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
U.S. Physical Therapy (NYSE:USPH) Frequently Asked Questions
What is U.S. Physical Therapy's stock symbol?
U.S. Physical Therapy trades on the New York Stock Exchange (NYSE) under the ticker symbol "USPH."
How often does U.S. Physical Therapy pay dividends? What is the dividend yield for U.S. Physical Therapy?
U.S. Physical Therapy announced a quarterly dividend on Wednesday, July 3rd. Shareholders of record on Thursday, August 15th will be given a dividend of $0.30 per share on Friday, September 13th. This represents a $1.20 annualized dividend and a yield of 0.90%. The ex-dividend date is Wednesday, August 14th. This is a positive change from U.S. Physical Therapy's previous quarterly dividend of $0.27. View U.S. Physical Therapy's Dividend History.
How were U.S. Physical Therapy's earnings last quarter?
U.S. Physical Therapy, Inc. (NYSE:USPH) announced its quarterly earnings results on Thursday, August, 8th. The company reported $0.81 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.81. The company had revenue of $126.40 million for the quarter, compared to analyst estimates of $124.86 million. U.S. Physical Therapy had a return on equity of 19.19% and a net margin of 6.22%. The company's revenue for the quarter was up 9.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.73 EPS. View U.S. Physical Therapy's Earnings History.
When is U.S. Physical Therapy's next earnings date?
What guidance has U.S. Physical Therapy issued on next quarter's earnings?
U.S. Physical Therapy issued an update on its FY19 earnings guidance on Thursday, August, 8th. The company provided earnings per share (EPS) guidance of $2.87-2.97 for the period, compared to the Thomson Reuters consensus estimate of $2.93.
What price target have analysts set for USPH?
3 brokerages have issued twelve-month target prices for U.S. Physical Therapy's shares. Their forecasts range from $106.61 to $107.00. On average, they anticipate U.S. Physical Therapy's stock price to reach $106.8050 in the next year. This suggests that the stock has a possible downside of 19.7%. View Analyst Price Targets for U.S. Physical Therapy.
What is the consensus analysts' recommendation for U.S. Physical Therapy?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for U.S. Physical Therapy in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for U.S. Physical Therapy.
What are Wall Street analysts saying about U.S. Physical Therapy stock?
Here are some recent quotes from research analysts about U.S. Physical Therapy stock:
- 1. According to Zacks Investment Research, "U.S. Physical Therapy, Inc. is the largest publicly-traded, pure-play operator of outpatient physical and occupational therapy clinics. The clinics provide pre- and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, rehabilitation of injured workers and preventative care. USPh also manages several physical therapy facilities for third parties, including physician groups. Each of USPh's clinics are directed by a licensed physical therapist that drive patient volume via local physicians, former patients and other referral sources. Marketing representatives are used to further augment sales. Historically, USPh has grown its business through de novo development; approximately two-thirds of USPh clinics were originally start-ups. Strategic acquisitions, which accelerate the Company's growth, are structured like the de novo partnerships, with significant ownership retained by founders. " (9/13/2019)
- 2. Barrington Research analysts commented, "We think this guidance is likely conservative and would not be surprised to see the adjusted EPS guidance increase as early as next quarter. Our current adjusted EPS expectation is $2.92." (5/3/2019)
Has U.S. Physical Therapy been receiving favorable news coverage?
Press coverage about USPH stock has been trending somewhat negative recently, InfoTrie reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. U.S. Physical Therapy earned a news impact score of -1.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for U.S. Physical Therapy.
Who are some of U.S. Physical Therapy's key competitors?
Some companies that are related to U.S. Physical Therapy include SWEDISH ORPHAN/S (SWTUY), Haemonetics (HAE), DiaSorin (DSRLF), Dr.Reddy's Laboratories (RDY), Encompass Health (EHC), Beigene (BGNE), Sarepta Therapeutics (SRPT), Moderna (MRNA), Hikma Pharmaceuticals (HKMPF), ACADIA Pharmaceuticals (ACAD), Amarin (AMRN), Exelixis (EXEL), bluebird bio (BLUE), Medidata Solutions (MDSO) and Syneos Health (SYNH).
What other stocks do shareholders of U.S. Physical Therapy own?
Who are U.S. Physical Therapy's key executives?
U.S. Physical Therapy's management team includes the folowing people:
- Mr. Christopher J. Reading, Pres, CEO & Director (Age 55)
- Mr. Lawrance W. McAfee, Exec. VP, CFO & Director (Age 64)
- Mr. Glenn D. McDowell, Chief Operating Officer of West (Age 62)
- Mr. Graham Reeve M.B.A., P.T., Chief Operating Officer of East (Age 55)
- Mr. Jon C. Bates, VP & Corp. Controller
Who are U.S. Physical Therapy's major shareholders?
U.S. Physical Therapy's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (17.70%), BlackRock Inc. (17.69%), Kayne Anderson Rudnick Investment Management LLC (10.91%), Price T Rowe Associates Inc. MD (8.26%), Vanguard Group Inc. (6.91%) and Riverbridge Partners LLC (3.04%). Company insiders that own U.S. Physical Therapy stock include Bernard A Harris Jr, Christopher J Reading, Clayton Trier, Edward L Kuntz, Glenn Mcdowell, Graham D Reeve, Harry S Chapman, Jerald L Pullins, Kathleen A Gilmartin, Lawrance W Mcafee, Mark J Brookner and Regg E Swanson. View Institutional Ownership Trends for U.S. Physical Therapy.
Which major investors are selling U.S. Physical Therapy stock?
USPH stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Bank of America Corp DE, Schroder Investment Management Group, Schroder Investment Management Group, Bank of New York Mellon Corp, Invesco Ltd., First Trust Advisors LP and THB Asset Management. Company insiders that have sold U.S. Physical Therapy company stock in the last year include Christopher J Reading, Clayton Trier, Glenn Mcdowell, Graham D Reeve, Lawrance W Mcafee and Mark J Brookner. View Insider Buying and Selling for U.S. Physical Therapy.
Which major investors are buying U.S. Physical Therapy stock?
USPH stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., BlackRock Inc., Nuveen Asset Management LLC, Scout Investments Inc., Vanguard Group Inc., Copeland Capital Management LLC, Los Angeles Capital Management & Equity Research Inc. and Morgan Stanley. Company insiders that have bought U.S. Physical Therapy stock in the last two years include Harry S Chapman, Kathleen A Gilmartin and Regg E Swanson. View Insider Buying and Selling for U.S. Physical Therapy.
How do I buy shares of U.S. Physical Therapy?
Shares of USPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is U.S. Physical Therapy's stock price today?
One share of USPH stock can currently be purchased for approximately $133.02.
How big of a company is U.S. Physical Therapy?
U.S. Physical Therapy has a market capitalization of $1.70 billion and generates $453.91 million in revenue each year. The company earns $34.87 million in net income (profit) each year or $2.65 on an earnings per share basis. U.S. Physical Therapy employs 4,600 workers across the globe.View Additional Information About U.S. Physical Therapy.
What is U.S. Physical Therapy's official website?
How can I contact U.S. Physical Therapy?
U.S. Physical Therapy's mailing address is 1300 WEST SAM HOUSTON PARKWAY SUITE 300, HOUSTON TX, 77042. The company can be reached via phone at 713-297-7000 or via email at [email protected]
MarketBeat Community Rating for U.S. Physical Therapy (NYSE USPH)
MarketBeat's community ratings are surveys of what our community members think about U.S. Physical Therapy and other stocks. Vote "Outperform" if you believe USPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe USPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
